Burosumab versus continuation of conventional therapy in children with X-linked hypophosphatemia: a randomised, active-controlled, open-label, phase 3 trial

BACKGROUND: X-linked hypophosphatemia in children is characterized by elevated serum FGF23, hypophosphatemia, rickets, lower extremity bowing, and growth impairment. We compared the efficacy and safety of continuing conventional therapy, consisting of oral phosphate and active vitamin D, versus swit...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet
Asıl Yazarlar: Imel, Erik A., Glorieux, Francis H., Whyte, Michael P., Munns, Craig F., Ward, Leanne, Nilsson, Ola, Simmons, Jill H., Padidela, Raja, Namba, Noriyuki, Cheong, Hae Il, Pitukcheewanont, Pisit, Sochett, Etienne, Högler, Wolfgang, Muroya, Koji, Tanaka, Hiroyuki, Gottesman, Gary S., Biggin, Andrew, Perwad, Farzana, Mao, Meng, Chen, Chao-Yin, Skrinar, Alison, Martin, Javier San, Portale, Anthony A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7179969/
https://ncbi.nlm.nih.gov/pubmed/31104833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(19)30654-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller